DYRK1A,

related kinases

& human disease conference

Saint-Malo, France
November 22-26, 2022

General information

General presentation

All major physiological phenomena are regulated by protein phosphorylation which is catalysed by protein kinases. Many diseases are associated with abnormal phosphorylation. Consequently, the last four decades have seen considerable efforts in the study of function and regulation of protein kinases in essentially all aspects of biology. In parallel, pharmacological inhibitors of kinases have become a major R&D area for the pharmaceutical industry in its search for new therapies. As of early 2020, 49 kinase inhibitors have reached the pharmaceutical market.

DYRKs (‘dual specificity, tyrosine phosphorylation regulated kinase 1’) (DYRK1A, 1B, 2, 3, 4) play key roles in mRNA splicing, chromatin transcription, DNA damage repair, cell survival, cell cycle, differentiation, endocytosis, neuronal development and functions, synaptic plasticity, folate and methionine metabolism. Inhibition of DYRKs may find applications in Down syndrome, Alzheimer’s disease and tauopathies, Parkinson’s disease, CDKL5 Deficiency Disorder diabetes, osteoarthritis, viral infections and various cancers. The closely related CLKs (‘cdc2-like kinases) (CLK1, 2, 3, 4) also play essential functions in Alzheimer’s disease and tauopathies, alternative splicing, various viral infections, cancers, body temperature sensing. DYRK and CLK orthologs are found in plants, yeast and unicellular parasites.

 

The conference will focus on DYRK1A and related kinases, including structural, regulatory and functional aspects, substrates and interactors, functions at cell and organism levels as well as development and potential therapeutic use of selective pharmacological inhibitors.

Location

Palais du Grand Large, St Malo, Bretagne, France

www.pgl-congres.com

 

Scientific information

 
Organizers
laurentmeijer.jpg

Laurent MEIJER

Perha Pharmaceuthicals,

Roscoff, France

masatoshi.jpg

Masatoshi HAGIWARA

Department of Anatomy

& Developmental Biology,

Graduate School of Medicine,

Kyoto University, Kyoto, Japan

Picture1.jpg

Peter P. DE DEYN

Department of Neurology,

General Hospital Middelheim and Institute Born-Bunge University of Antwerp,

Antwerpen, Belgium

Contact

Mariona ARBONES, Barcelona, Spain

          Insights into the early neurogenic defects in DYRK1A haplo-insufficient syndrome

Walter BECKER, Aachen, Germany

          DYRK1B – a cancer drug target?

Mara DIERSSEN, Barcelona, Spain

          Role of DYRK1A in glucose homeostasis and food intake

Jean DELABAR, Paris, France

          DYRK1A, biomarker of target for Alzheimer's disease?

Peter DE DEYN, Antwerpen, Belgium

          Down syndrome, Alzheimer’s disease & DYRK1A

 

Masatoshi HAGIWARA, Kyoto, Japan

          Development of inhibitors of CDK9, CLK1 and DYRK1A, and their clinical applications

 

Yann HERAULT, Strasbourg, France

         DYRK1A dosage and cognition deficit in animal models of human disease

 

Nathalie JANEL, Paris, France

          DYRK1A interactants, a link between Down's syndrome and its comorbidities

Bernard KHOR, Seattle, USA

          DYRK family members and autoimmunity

Stefan KNAPP, Frankfurt, Germany

          Selective targeting of kinases regulation RNA splicing

 

Akiko KOBAYASHI, Kyoto, Japan

          Neuroprotection through suppression of inflammation by DYRK inhibitors

 

Reinhardt W. KÖSTER, Braunschweig, Germany

          A zebrafish model for studying DYRK1A hyperactivity in the cerebellum

Sébastien MALINGE, Perth, Australia

          DYRK1A and Acute Lymphoblastoid Leukemia

Laurent MEIJER, Roscoff, France

          Leucettinibs, a second-generation family of DYRKs/CLKs inhibitors: from natural products to clinical

          applications

Christopher MEISINGER, Freiburg, Germany

          The role of DYRK1A in mitochondrial protein import

Jamileh MOVASSAT, Paris, France

          DYRK1A inhibitors for beta cell proliferation to treat diabetes

Lucas PELKMANS, Zurich, Switzerland

          DYRK kinases as regulators of intracellular condensates

Amélie PITON, Illkirch, France

          Characterization of DYRK1A syndrome, a frequent form of neurodevelopmental disorder

Victor TYBULEWICZ

          Congenital heart defects in Down Syndrome are caused by inscreased dosage of DYRK1A

Invited speakers
Program

The final program will be available in October 2022.

Abstract submission

Organization: Arial 11, 1 page maximum, title (bold), authors (underline presenting author), addresse-mail contactabstract, 1-3 compact references, (funding). Save under ‘yourname.doc’ or ‘yourname.docx’.

Submit abstract as an attached Word document, through the Conference e-mail address                                   (dyrk-conference@perha-pharma.com), with your name as ‘subject’.

Abstract submission deadline: September 30, 2022.

.

Instructions for speakers

There will be no poster sessions. We will try to have as many people as possible, especially students and post-docs, presenting their results. Besides invited speakers, submitted abstracts will be selected for long (15 min) or short (5 min) oral presentations (+ 5 min discussion).

Registration

& Accommodation

Registration
Important dates

Very early bird registration deadline: July 31, 2022.

Early bird registration deadline: September 4, 2022.

Late registration: September 4 up to October 31, 2022.

Start of the conference: November 22, 2022 at 17:00.

End of the conference: November 26, 2022 at 12:00.

Registration cost

Registration comprises access to all conferences, program, coffee/tea breaks and lunches.

 

Very early bird registration deadline:

Industry: 600 €                        Academy: 500 €                      PhD Students*: 300 €.

Early bird registration deadline:

Industry: 800 €                        Academy: 600 €                      PhD Students*: 400 €.

Late registration:

Industry: 1000 €                      Academy: 700 €.                     PhD Students*: 500 €.

                                                                                                 * Photocopy of student card required

Accommodation

Please consult our list of accommodation here.

 
saint-malo2.jpg

Travel

Travel grants for young researchers

The « Fondation Vaincre Alzheimer » is open to receive travel grant applications from young researchers.  Do not hesitate to submit your application at: https://www.vaincrealzheimer.org/espace-chercheur-bourse-voyage/

Getting to Saint-Malo

The easiest: Fast train (TGV) from Paris-Montparnasse train station.

Please consult our information for international access here.

Saint-Malo & Brittany

Tourism office: www.saint-malo-tourisme.com

Saint-Malo city hall: www.ville-saint-malo.fr

 
 

Sponsorship

& Exhibitions

Click on the logo to access the site.

perha-pharma.jpg
Vaincre Alzheimer.png
Campus de la Mer.png
J.Lejeune logo.png
T21RS ok.png
AdipoGen_Logo_LIFE SCIENCES_CMYK_2015_NEW_13cm_highres.jpg